Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment

Current Topics in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 11-31

  Ferrucci, P F ^a   Tosti, G ^a   di Pietro, A ^a   Passoni, C ^a   Pari, C ^a   Tedeschi, I ^a   Cataldo, F ^a   Martinoli, C ^a   Testori, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cancer testis; Heat shock proteins; Immunization vaccination; Immunotherapy; MAGE A3; Melanoma; Oncophage; Tumour antigens

Indexed keywords

ANTIBODY; CANCER VACCINE; CYTOKINE; HEAT SHOCK PROTEIN; TUMOR ANTIGEN; VITESPEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; FATIGUE; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; MELANOMA; NAUSEA; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 84855835850     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612798919213     Document Type: Review

References (192)

1. Eggermont, A. M.; Kirkwood, J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer, 2004, 40, 1825-1836.
2. Atkins, M. B.;Lotze, M.T.;Dutcher, J.P.;Fisher, R.I.;Weiss, G.;Margolin, K.;Abrams, J.;Sznol, M.;Parkinson, D.;Hawkins, M.;Paradise, C.;Kunkel, L.;Rosenberg, S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 1999, 17, 2105-2116.
3. Kirkwood, J. M. andErnstoff, M. Melanoma: therapeutic options with recombinant interferons. Semin. Oncol., 1985, 12, 7-12.
4. Kirkwood, J. M.; Ernstoff, M.S.; Davis, C.A.; Reiss, M.; Ferraresi, R.; Rudnick, S.A. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann. Intern. Med.,1985, 103, 32-36.
5. Kirkwood, J. M.; Ibrahim, J.G.; Sondak, V.K.; Richards, J.; Flaherty, L.E.; Ernstoff, M.S.; Smith, T.J.; Rao, U.; Steele, M.; Blum, R.H. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol., 2000, 18, 2444-2458.
6. Kirkwood, J. M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol., 2001, 19, 2370-2380.
7. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer Statistics, 2010. CA Cancer J. Clin., 2010, 60(5), 277-300
8. Balch, C. M.; Gershenwald, J.E.; Soong, S.J.; Thompson, J.F.; Atkins, M.B.; Byrd, D.R.; Buzaid, A.C.; Cochran, A.J.; Coit, D.G.; Ding, S.; Eggermont, A.M.; Flaherty, K.T.; Gimotty, P.A.; Kirkwood, J.M.; McMasters, K.M.; Mihm, M.C. Jr.; Morton, D.L.; Ross, M.I.; Sober, A.J.; Sondak, V.K. Final version of 2009 AJCC melanoma staging and classification. J. Clin Oncol., 2009, 27, 6199-6206.
9. Galanis, E. Technology evaluation: Allovectin-7, Vical. Curr. Opin. Mol. Ther., 2002, 4, 80-87.
10. Bedikian, A. Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, U.; Pavlick, A.C.; DeConti, R.; Hersh, E.M.; Hersey, P.; Kirkwood, J.M.; Haluska, F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol., 2006, 24, 4738-4745.
11. O'Donnel, A.; Faivre, S.; Judson, I.; Delbado, C.; C.; Lane, Brock, H.; Shand, N.; Hazell, K.; Armand, J.-P.; Raymond; E. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc Am Soc Clin Onc (ASCO)., 2003, 22, (abstr 803) ASCO Annual Meeting.
12. Morabito, A.; De Maio, E.; Di Maio, M.; Normanno, N.; Perrone, F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist, 2006, 11, 753-764.
13. Margolin, K.; Longmate, J.; Baratta, T.; Synold, T.; Christensen, S.; Weber, J.; Gajewski, T.; Quirt, I.; Doroshow, J.H. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer, 2005, 104, 1045-1048.
14. Teft, W. A.; Kirchhof, M.G.; Madrenas, J. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol., 2006, 24, 65-97.
15. Weber, J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist, 2008, 13 (Suppl 4), 16-25.
16. Weber, J. S. Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma. J. Invest Dermatol., 2008, 128, 2750-2752.
17. Eisen, T.; Ahmad, T.; Flaherty, K.T.; Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L.M.; Nathanson, K.L.; Xia, C.; Simantov, R.; Schwartz, B.; Poulin-Costello, M.; O'Dwyer, P.J.; Ratain, M.J. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer., 2006, 95, 581-586.
18. Jager, E.; Jager, D.; Knuth, A. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer, 2003, 106, 817-820.
19. Dunn, G. P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 2002, 3, 991-998.
20. Bui, J. D.; Schreiber, R.D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol., 2007, 19, 203-208.
21. Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer zum Buschenfelde, K.H.; Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science., 1995, 269, 1281-1284.
22. Doggrell, S. A. 'Simply stunning'--trastuzumab in HER2-positive breast cancer. Expert. Opin. Pharmacother., 2006, 7, 631-634.
23. Stanley, M. A. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert. Rev. Vaccines, 2003, 2, 381-389.
24. de Vries, T. J.; Smeets, M.; de Graaf, R.; Hou-Jensen, K.; Brocker, E.B.; Renard, N.; Eggermont, A.M.; van Muijen, G.N.; Ruiter, D.J. Expression of gp100, MART-1, tyrosinase, and S100 in paraffinembedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J. Pathol., 2001, 193, 13-20.
25. Kawakami, Y.; Eliyahu, S.; Delgado, C.H.; Robbins, P.F.; Sakaguchi, K.; Appella, E.; Yannelli, J.R.; Adema, G.J.; Miki, T.; Rosenberg, S.A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 1994, 91, 6458-6462.
26. Heslop, H. E.; Stevenson, F.K.; Molldrem, J.J. Immunotherapy of hematologic malignancy. Hematology. Am Soc Hematol. Educ. Program, 2003, 331-349.
27. Coulie, P. G.; Brichard, V.; Van Pel, A.; Wolfel, T.; Schneider, J.; Traversari, C.;Mattei, S.; De Plaen, E.; Lurquin, C.; Szikora, J.P.; Renauld, J.C.; Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLAA2 melanomas. J. Exp. Med., 1994, 180, 35-42.
28. Parmiani, G.; Castelli, C.; Santinami, M.; Rivoltini, L. Melanoma immunology: past, present and future. Curr. Opin. Oncol., 2007, 19, 121-127.
29. Terando, A. M.; Faries, M.B.; Morton, D.L. Vaccine therapy for melanoma: current status and future directions. Vaccine, 2007, 25 Suppl 2, B4-16.
30. Rosenberg, S. A.; Yang, J.C.; Robbins, P.F.; Wunderlich, J.R.; Hwu, P.; Sherry, R.M.; Schwartzentruber, D.J.; Topalian, S.L.; Restifo, N.P.; Filie, A.; Chang, R.; Dudley, M.E. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother., 2003, 26, 385-393.
31. Kawakami, Y.; Wang, X.; Shofuda, T.; Sumimoto, H.; Tupesis, J.; Fitzgerald, E.; Rosenberg, S. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J. Immunol., 2001, 166, 2871-2877.
32. Caballero, O. L.; Chen, Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci., 2009, 100, 2014-2021.
33. Rivoltini, L.; Castelli, C.; Carrabba, M.; Mazzaferro, V.; Pilla, L.; Huber, V.; Coppa, J.; Gallino, G.; Scheibenbogen, C.; Squarcina, P.; Cova, A.; Camerini, R.; Lewis, J.J.; Srivastava, P.K.; Parmiani, G. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of mela. J. Immunol., 2003, 171, 3467-3474.
34. Belli, F.; Testori, A.; Rivoltini, L.; Maio, M.; Andreola, G.; Sertoli, M.R.; Gallino, G.; Piris, A.; Cattelan, A.; Lazzari, I.; Carrabba, M.; Scita, G.; Santantonio, C.; Pilla, L.;Tragni, G.; Lombardo, C.; Arienti, F.; Marchiano, A.; Queirolo, P.; Bertolini, F.; Cova, A.; Lamaj, E.; Ascani, L.; Camerini, R.; Corsi, M.; Cascinelli, N.; Lewis, J.J.; Srivastava, P.; Parmiani, G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol.,2002, 20, 4169-4180.
35. Testori, A.; Richards, J.; Whitman, E.; Mann, G.B.; Lutzky, J.; Camacho, L.; Parmiani, G.; Tosti, G.; Kirkwood, J.M.; Hoos, A.; Yuh, L.; Gupta, R.; Srivastava, P.K. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol., 2008, 26, 955-962.
36. Herin, M.; Lemoine, C.; Weynants, P.; Vessiere, F.; Van Pel, A.; Knuth, A.; Devos, R.; Boon, T. Production of stable cytolytic Tcell clones directed against autologous human melanoma. Int. J. Cancer, 1987, 39, 390-396.
37. Vanky, F.; Gorsky, T.; Gorsky, Y.; Masucci, M.G.; Klein, E. Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. J. Exp. Med., 1982, 155, 83-95.
38. Mukherji, B.; MacAlister, T.J. Clonal analysis of cytotoxic T cell response against human melanoma. J. Exp. Med., 1983, 158, 240-245.
39. Knuth, A.; Danowski, B.; Oettgen, H.F.; Old, L.J. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl. Acad. Sci. USA, 1984, 81, 3511-3515.
40. Anichini, A.; Fossati, G.; Parmiani, G. Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. Int. J. Cancer, 1985, 35, 683-689.
41. Crowley, N. J.; Darrow, T.L.; Quinn-Allen, M.A.; Seigler, H.F. MHC-restricted recognition of autologous melanoma by tumorspecific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J. Immunol., 1991, 146, 1692-1699.
42. Ohnmacht, C.; Pullner, A.; King, S.B.; Drexler, I.; Meier, S.; Brocker, T.; Voehringer, D. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med., 2009, 206, 549-559.
43. Gogas, H.; Ioannovich, J.; Dafni, U.; Stavropoulou-Giokas, C.; Frangia, K.; Tsoutsos, D.; Panagiotou, P.;Polyzos, A.;Papadopoulos, O.;Stratigos, A.;Markopoulos, C.;Bafaloukos, D.;Pectasides, D.;Fountzilas, G.;Kirkwood, J.M. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med., 2006, 354, 709-718.
44. Bouwhuis, M. G.;Suciu, S.;Collette, S.;Aamdal, S.;Kruit, W.H.;Bastholt, L.;Stierner, U.;Sales, F.;Patel, P.;Punt, C.J.;Hernberg, M.;Spatz, A.;ten Hagen, T.L.;Hansson, J.;Eggermont, A.M. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J. Natl. Cancer Inst., 2009, 101, 869-877.
45. Shimizu, J.;Yamazaki, S.;Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163, 5211-5218.
46. Eggermont, A. M. Immunotherapy: Vaccine trials in melanoma--time for reflection. Nat. Rev. Clin Oncol., 2009, 6, 256-258.
47. Buckwalter, M. R. andSrivastava, P.K. "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. Semin. Immunol., 2008, 20, 296-300.
48. Ray, S.;Chhabra, A.;Mehrotra, S.;Chakraborty, N.G.;Ribas, A.;Economou, J.;Mukherji, B. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol., 2009, 27, 603-613.
49. Brenner, D.;Krammer, P.H.;Arnold, R. Concepts of activated T cell death. Crit Rev. Oncol Hematol., 2008, 66, 52-64.
50. Lenardo, M. J. Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system. Immunol. Res., 2003, 27, 387-398.
51. Chhabra, A.;Mehrotra, S.;Chakraborty, N.G.;Dorsky, D.I.;Mukherji, B. Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosisinducing factor. Eur. J. Immunol., 2006, 36, 3167-3174.
52. Barber, D. L.;Wherry, E.J.;Masopust, D.;Zhu, B.;Allison, J.P.;Sharpe, A.H.;Freeman, G.J.;Ahmed, R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature., 2006, 439, 682-687.
53. Rabinovich, G. A.;Gabrilovich, D.;Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 2007, 25, 267-296.
54. Morris, E. C.;Tsallios, A.;Bendle, G.M.;Xue, S.A.;Stauss, H.J. A critical role of T cell antigen receptor-transduced MHC class Irestricted helper T cells in tumor protection. Proc Natl. Acad. Sci. U. S. A., 2005, 102, 7934-7939.
55. Kolmel, K. F.;Pfahlberg, A.;Mastrangelo, G.;Niin, M.;Botev, I.N.;Seebacher, C.;Schneider, D.;Lambert, D.;Shafir, R.;Kokoschka, E.M.;Kleeberg, U.R.;Henz, B.M.;Gefeller, O. Infections and melanoma risk: results of a multicentre EORTC casecontrol study. European Organization for Research and Treatment of Cancer. Melanoma Res., 1999, 9, 511-519.
56. Grange, J. M.;Krone, B.;Stanford, J.L. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth. Eur. J. Cancer., 2009, 45, 2266-2273.
57. Hoon, D. S.; Korn, E.L.; Cochran, A.J. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res., 1987, 47, 1740-1744.
58. Penn, I. Cancer in immunosuppressed patients. Transplant. Proc., 1984, 16, 492-494.
59. Sheil, A. G.; Flavel, S.; Disney, A.P.; Mathew, T.H. Cancer development in patients progressing to dialysis and renal transplantation. Transplant. Proc., 1985, 17, 1685-1688.
60. Javia, L. R.;Rosenberg, S.A. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother., 2003, 26, 85-93.
61. Viguier, M.; Lemaitre, F.; Verola, O.; Cho, M.S.; Gorochov, G.; Dubertret, L.; Bachelez, H.; Kourilsky, P.; Ferradini, L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol., 2004, 173, 1444-1453.
62. Valenti, R.; Huber, V.; Filipazzi, P.; Pilla, L.; Sovena, G.; Villa, A.; Corbelli, A.; Fais, S.; Parmiani, G.; Rivoltini, L. Human tumorreleased microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res., 2006, 66, 9290-9298.
63. Andreola, G.; Rivoltini, L.; Castelli, C.; Huber, V.; Perego, P.; Deho, P.; Squarcina, P.; Accornero, P.; Lozupone, F.; Lugini, L.; Stringaro, A.; Molinari, A.; Arancia, G.; Gentile, M.; Parmiani, G.; Fais, S. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med., 2002, 195, 1303-1316.
64. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol., 2006, 6, 295-307.
65. Guy, B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol., 2007, 5, 505-517.
66. Ulmer, J. B.; Wahren, B.; Liu, M.A. DNA vaccines: recent technological and clinical advances. Discov. Med., 2006, 6, 109-112.
67. Hunter, R. L. Overview of vaccine adjuvants: present and future. Vaccine., 2002, 20 Suppl 3, S7-12.
68. Schnurr, M.; Chen, Q.; Shin, A.; Chen, W.; Toy, T.; Jenderek, C.; Green, S.; Miloradovic, L.; Drane, D.; Davis, I.D.; Villadangos, J.; Shortman, K.; Maraskovsky, E.; Cebon, J. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood., 2005, 105, 2465-2472.
69. Sanders, M. T.; Brown, L.E.; Deliyannis, G.; Pearse, M.J. ISCOMbased vaccines: the second decade. Immunol. Cell Biol., 2005, 83, 119-128.
70. Leserman, L. Liposomes as protein carriers in immunology. J. Liposome Res., 2004, 14, 175-189.
71. O'Hagan, D. T.;Singh, M. Microparticles as vaccine adjuvants and delivery systems. Expert. Rev. Vaccines., 2003, 2, 269-283.
72. Singh, M.; Kazzaz, J.; Ugozzoli, M.; Malyala, P.; Chesko, J.; O'Hagan, D.T. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv., 2006, 3, 115-120.
73. Baselli, E. C.;Greenberg, R.E. Intravesical therapy for superficial bladder cancer. Oncology (Williston. Park)., 2000, 14, 719-729.
74. Uyl-de Groot, C. A.; Vermorken, J.B.; Hanna, M.G. Jr.; Verboom, P.; Groot, M.T.; Bonsel, G.J.; Meijer, C.J.; Pinedo, H.M. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine., 2005, 23, 2379-2387.
75. Motl, S. E. Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax. Curr. Opin. Mol. Ther., 2004, 6, 104-111.
76. Kelland, L. Discontinued drugs in 2005: oncology drugs. Expert. Opin. Investig. Drugs. 2006, 15, 1309-1318.
77. Aucouturier, J.; Dupuis, L.; Deville, S.; Ascarateil, S.; Ganne, V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert. Rev. Vaccines., 2002, 1, 111-118.
78. Cluff, C. W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol., 2009, 667, 111-123.
79. Speiser, D. E.;Romero, P. Toward improved immunocompetence of adoptively transferred CD8+ T cells. J. Clin Invest., 2005, 115, 1467-1469.
80. Speiser, D. E.; Lienard, D.; Rufer, N.; Rubio-Godoy, V.; Rimoldi, D.; Lejeune, F.; Krieg, A.M.; Cerottini, J.C.; Romero, P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin Invest., 2005, 115, 739-746.
81. Atanackovic, D.; Altorki, N.K.; Cao, Y.; Ritter, E.; Ferrara, C.A.; Ritter, G.; Hoffman, E.W.; Bokemeyer, C.; Old, L.J.; Gnjatic, S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl. Acad. Sci. USA, 2008, 105, 1650-1655.
82. Ren, W.; Strube, R.; Zhang, X.; Chen, S.Y.; Huang, X.F. Potent tumor-specific immunity induced by an in vivo heat shock proteinsuicide gene-based tumor vaccine. Cancer. Res., 2004, 64, 6645-6651.
83. Meidenbauer, N.; Zippelius, A.; Pittet, M.J.; Laumer, M.; Vogl, S.; Heymann, J.; Rehli, M.; Seliger, B.; Schwarz, S.; Le Gal, F.A.; Dietrich, P.Y.; Andreesen, R.; Romero, P.; Mackensen, A. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer. Res., 2004, 64, 6319-6326.
84. Krieg, A. M. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev., 2001, 11, 181-188.
85. Boon, T.; Coulie, P.; Marchand, M.; Weynants, P.; Wolfel, T.; Brichard, V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol., 1994, 53-69.
86. Boon, T.; Coulie, P.G.; Van den, E.B. Tumor antigens recognized by T cells. Immunol. Today., 1997, 18, 267-268.
87. Chen, Y. T.; Scanlan, M.J.; Sahin, U.; Tureci, O.; Gure, A.O.; Tsang, S.; Williamson, B.; Stockert, E.; Pfreundschuh, M.; Old, L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl. Acad. Sci. USA, 1997, 94, 1914-1918.
88. Old, L. J. Cancer/testis (CT) antig. Cancer. Immun., 2001, 1, 1-
89. Old, L. J. Cancer vaccines: an overview. Cancer Immun., 2008, 8(Suppl 1), 1-
90. Brasseur, F.; Rimoldi, D.; Lienard, D.; Lethe, B.; Carrel, S.; Arienti, F.; Suter, L.; Vanwijck, R.; Bourlond, A.; Humblet, Y. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer, 1995, 63, 375-380.
91. Kurashige, T.; Noguchi, Y.; Saika, T.; Ono, T.; Nagata, Y.; Jungbluth, A.; Ritter, G.; Chen, Y.T.; Stockert, E.; Tsushima, T.; Kumon, H.; Old, L.J.; Nakayama, E. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res., 2001, 61, 4671-4674.
92. Bredenbeck, A.; Losch, F.O.; Sharav, T.; Eichler-Mertens, M.; Filter, M.; Givehchi, A.; Sterry, W.; Wrede, P.; Walden, P. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. J. Immunol., 2005, 174, 6716-6724.
93. Halama, N.; Zoernig, I.; Jaeger, D. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J. Oncol., 2010, 2010, 689893.
94. Boel, P.; Wildmann, C.; Sensi, M.L.; Brasseur, R.; Renauld, J.C.; Coulie, P.; Boon, T.; van der, B.P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity., 1995, 2, 167-175.
95. Levy, F.; Colombetti, S. Promises and limitations of murine models in the development of anticancer T-cell vaccines. Int. Rev. Immunol., 2006, 25, 269-295.
96. van der, B. P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den, E.B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254, 1643-1647.
97. Boon, T.; van der, B.P. Human tumor antigens recognized by T lymphocytes. J Exp. Med., 1996, 183, 725-729.
98. Van den, E. B.; Peeters, O.; De Backer, O.; Gaugler, B.; Lucas, S.; Boon, T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med., 1995, 182, 689-698.
99. Gaugler, B.; Van den, E.B.; van der, B.P.; Romero, P.; Gaforio, J.J.; De Plaen, E.; Lethe, B.; Brasseur, F.; Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 1994, 179, 921-930.
100. Jager, D.; Stockert, E.; Gure, A.O.; Scanlan, M.J.; Karbach, J.; Jager, E.; Knuth, A.; Old, L.J.; Chen, Y.T. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer. Res.; 2001, 61, 2055-2061.
101. Sahin, U.; Tureci, O.; Pfreundschuh, M. Serological identification of human tumor antigens. Curr. Opin. Immunol., 1997, 9, 709-716.
102. Sahin, U.; Tureci, O.; Schmitt, H.; Cochlovius, B.; Johannes, T.; Schmits, R.; Stenner, F.; Luo, G.; Schobert, I.; Pfreundschuh, M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA, 1995, 92, 11810-11813.
103. Chen, Y. T.; Gure, A.O.; Tsang, S.; Stockert, E.; Jager, E.; Knuth, A.; Old, L.J. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. USA, 1998, 95, 6919-6923.
104. Jungbluth, A. A.; Silva, W.A. Jr.; Iversen, K.; Frosina, D.; Zaidi, B.; Coplan, K.; Eastlake-Wade, S.K.; Castelli, S.B.; Spagnoli, G.C.; Old, L.J.; Vogel, M. Expression of cancer-testis (CT) antigens in placenta. Cancer. Immun., 2007, 7, 15-
105. De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.;De Smet, C.;Brasseur, F.; van der, B.P.; Lethe, B.; Lurquin, C. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics., 1994, 40, 360-369.
106. Patard, J. J.; Brasseur, F.; Gil-Diez, S.; Radvanyi, F.; Marchand, M.; Francois, P.; Abi-Aad, A.; Van Cangh, P.; Abbou, C.C.; Chopin, D. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer., 1995, 64, 60-64.
107. Gure, A. O.; Chua, R.; Williamson, B.; Gonen, M.; Ferrera, C.A.; Gnjatic, S.; Ritter, G.; Simpson, A.J.; Chen, Y.T.; Old, L.J.; Altorki, N.K. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res., 2005, 11, 8055-8062.
108. Peikert, T.; Specks, U.; Farver, C.; Erzurum, S.C.; Comhair, S.A. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer. Res., 2006, 66, 4693-4700.
109. Monte, M.; Simonatto, M.; Peche, L.Y.; Bublik, D.R.; Gobessi, S.; Pierotti, M.A.; Rodolfo, M.; Schneider, C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA, 2006, 103, 11160-11165.
110. Yang, B.; O'Herrin, S.M.; Wu, J.; Reagan-Shaw, S.; Ma, Y.; Bhat, K.M.; Gravekamp, C.; Setaluri, V.; Peters, N.; Hoffmann, F.M.; Peng, H.; Ivanov, A.V.; Simpson, A.J.; Longley, B.J. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer. Res., 2007, 67, 9954-9962.
111. Zhu, X.; Asa, S.L.; Ezzat, S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin. Cancer Res., 2008, 14, 1984-1996.
112. Duan, Z.; Duan, Y.; Lamendola, D.E.; Yusuf, R.Z.; Naeem, R.; Penson, R.T.; Seiden, M.V. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer. Res., 2003, 9, 2778-2785.
113. Fukuyama, T.; Hanagiri, T.; Takenoyama, M.; Ichiki, Y.; Mizukami, M.; So, T.; Sugaya, M.; So, T.; Sugio, K.; Yasumoto, K. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer. Res., 2006, 66, 4922-4928.
114. Xing, Q.; Pang, X.W.; Peng, J.R.; Yin, Y.H.; Li, Y.; Yu, X.; Zhou, S.P.; Zhang, Y.; Chen, W.F. Identification of new cytotoxic Tlymphocyte epitopes from cancer testis antigen HCA587. Biochem. Biophys. Res. Commun., 2008, 372, 331-335.
115. Frank, C.; Hundemer, M.; Ho, A.D.; Goldschmidt, H.; Witzens-Harig, M. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk. Lymphoma., 2008, 49, 779-785.
116. Ait-Tahar, K.; Liggins, A.P.; Collins, G.P.; Campbell, A.; Barnardo, M.; Lawrie, C.; Moir, D.; Hatton, C.; Banham, A.H.; Pulford, K. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br. J. Haematol., 2009, 146, 396-407.
117. Jager, E.; Stockert, E.; Zidianakis, Z.; Chen, Y.T.; Karbach, J.; Jager, D.; Arand, M.; Ritter, G.; Old, L.J.; Knuth, A. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer, 1999, 84, 506-510.
118. Mischo, A.; Kubuschok, B.; Ertan, K.; Preuss, K.D.; Romeike, B.; Regitz, E.; Schormann, C.; de Bruijn, D.; Wadle, A.; Neumann, F.; Schmidt, W.; Renner, C.; Pfreundschuh, M. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int. J. Cancer, 2006, 118, 696-703.
119. Eichmuller, S.; Usener, D.; Thiel, D.; Schadendorf, D. Tumorspecific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. Int. J Cancer, 2003, 104, 482-487.
120. Baxevanis, C. N.; Voutsas, I.F.; Tsitsilonis, O.E.; Gritzapis, A.D.; Sotiriadou, R.; Papamichail, M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol., 2000, 164, 3902-3912.
121. Janssen, E. M.; Lemmens, E.E.; Wolfe, T.; Christen, U.; von Herrath, M.G.; Schoenberger, S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature, 2003, 421, 852-856.
122. Shedlock, D. J.; Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 2003, 300, 337-339.
123. Sun, J. C.; Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science, 2003, 300, 339-342.
124. Bayry, J.; Triebel, F.; Kaveri, S.V.;Tough, D.F. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J. Immunol., 2007, 178, 4184-4193.
125. Kruit, W. H.; van Ojik, H.H.; Brichard, V.G.; Escudier, B.; Dorval, T.; Dreno, B.; Patel, P.; van Baren, N.; Avril, M.F.; Piperno, S.; Khammari, A.; Stas, M.; Ritter, G.; Lethe, B.; Godelaine, D.; Brasseur, F.; Zhang, Y.; van der, B.P.; Boon, T.; Eggermont, A.M.; Marchand, M. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer, 2005, 117, 596-604.
126. Banchereau, J.; Palucka, A.K.; Dhodapkar, M.; Burkeholder, S.; Taquet, N.; Rolland, A.; Taquet, S.; Coquery, S.; Wittkowski, K.M.; Bhardwaj, N.; Pineiro, L.; Steinman, R.; Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 2001, 61, 6451-6458.
127. Schuler-Thurner, B.; Schultz, E.S.; Berger, T.G.; Weinlich, G.; Ebner, S.; Woerl, P.; Bender, A.; Feuerstein, B.; Fritsch, P.O.; Romani, N.; Schuler, G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med., 2002, 195, 1279-1288.
128. Marchand, M.; Weynants, P.; Rankin, E.; Arienti, F.; Belli, F.; Parmiani, G.; Cascinelli, N.; Bourlond, A.; Vanwijck, R.; Humblet, Y. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 1995, 63, 883-885.
129. Marchand, M.; van Baren, N.; Weynants, P.; Brichard, V.; Dreno, B.; Tessier, M.H.; Rankin, E.; Parmiani, G.; Arienti, F.; Humblet, Y.; Bourlond, A.; Vanwijck, R.; Lienard, D.; Beauduin, M.; Dietrich, P.Y.; Russo, V.; Kerger, J.; Masucci, G.; Jager, E.; De Greve, J.; Atzpodien, J.; Brasseur, F.; Coulie, P.G.; van der, B.P.; Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 1999, 80, 219-230.
130. Weber, J. S.; Hua, F.L.; Spears, L.; Marty, V.; Kuniyoshi, C.; Celis, E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother., 1999, 22, 431-440.
131. Thurner, B.; Haendle, I.; Roder, C.; Dieckmann, D.; Keikavoussi, P.; Jonuleit, H.; Bender, A.; Maczek, C.; Schreiner, D.; von den, D.P.; Brocker, E.B.; Steinman, R.M.; Enk, A.; Kampgen, E.; Schuler, G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med., 1999, 190, 1669-1678.
132. Fay, J. W.; Palucka, A.K.; Paczesny, S.; Dhodapkar, M.; Johnston, D.A.; Burkeholder, S.; Ueno, H.; Banchereau, J. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother., 2006, 55, 1209-1218.
133. Schuler-Thurner, B.; Dieckmann, D.; Keikavoussi, P.; Bender, A.; Maczek, C.; Jonuleit, H.; Roder, C.; Haendle, I.; Leisgang, W.; Dunbar, R.; Cerundolo, V.; von den, D.P.; Knop, J.; Brocker, E.B.; Enk, A.; Kampgen, E.; Schuler, G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol., 2000, 165, 3492-3496.
134. Banchereau, J.; Ueno, H.; Dhodapkar, M.; Connolly, J.; Finholt, J.P.; Klechevsky, E.; Blanck, J.P.; Johnston, D.A.; Palucka, A.K.; Fay, J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J. Immunother., 2005, 28, 505-516.
135. Hersey, P.; Menzies, S.W.; Coventry, B.; Nguyen, T.; Farrelly, M.; Collins, S.; Hirst, D.; Johnson, H. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol. Immunother., 2005, 54, 208-218.
136. Atanackovic, D.; Altorki, N.K.; Stockert, E.; Williamson, B.; Jungbluth, A.A.; Ritter, E.; Santiago, D.; Ferrara, C.A.; Matsuo, M.; Selvakumar, A.; Dupont, B.; Chen, Y.T.; Hoffman, E.W.; Ritter, G.; Old, L.J.; Gnjatic, S. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol., 2004, 172, 3289-3296.
137. Marchand, M.; Punt, C.J.; Aamdal, S.; Escudier, B.; Kruit, W.H.; Keilholz, U.; Hakansson, L.; van Baren, N.; Humblet, Y.; Mulders, P.; Avril, M.F.; Eggermont, A.M.; Scheibenbogen, C.; Uiters, J.; Wanders, J.; Delire, M.; Boon, T.; Stoter, G. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer, 2003, 39, 70-77.
138. Hoos, A.; Parmiani, G.; Hege, K.; Sznol, M.; Loibner, H.; Eggermont, A.; Urba, W.; Blumenstein, B.; Sacks, N.; Keilholz, U.; Nichol, G. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother., 2007, 30, 1-15.
139. Vansteenkiste, J.; Zielinski, M.; Dahabreh, I.;et al. Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). JCO. 2006, Vol 24,
140. Brichard, V. G.; Lejeune, D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine, 2007, 25, 61-71.
141. Dave, S. S.; Wright, G.; Tan, B.; Rosenwald, A.; Gascoyne, R.D.; Chan, W.C.; Fisher, R.I.; Braziel, R.M.; Rimsza, L.M.; Grogan, T.M.; Miller, T.P.; LeBlanc, M.; Greiner, T.C.; Weisenburger, D.D.; Lynch, J.C.; Vose, J.; Armitage, J.O.; Smeland, E.B.; Kvaloy, S.; Holte, H.; Delabie, J.; Connors, J.M.; Lansdorp, P.M.; Ouyang, Q.; Lister, T.A.; Davies, A.J.; Norton, A.J.; Muller-Hermelink, H.K.; Ott, G.; Campo, E.; Montserrat, E.; Wilson, W.H.; Jaffe, E.S.; Simon, R.; Yang, L.; Powell, J.; Zhao, H.; Goldschmidt, N.; Chiorazzi, M.; Staudt, L.M. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N. Engl. J. Med., 2004, 351, 2159-2169.
142. Hu, Z.; Fan, C.; Oh, D.S.; Marron, J.S.; He, X.; Qaqish, B.F.; Livasy, C.; Carey, L.A.; Reynolds, E.; Dressler, L.; Nobel, A.; Parker, J.; Ewend, M.G.; Sawyer, L.R.; Wu, J.; Liu, Y.; Nanda, R.; Tretiakova, M.; Ruiz, O.A.; Dreher, D.; Palazzo, J.P.; Perreard, L.; Nelson, E.; Mone, M.; Hansen, H.; Mullins, M.; Quackenbush, J.F.; Ellis, M.J.; Olopade, O.I.; Bernard, P.S.; Perou, C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC. Genomics., 2006, 7, 96.
143. Weigelt, B.; Hu, Z.; He, X.; Livasy, C.; Carey, L.A.; Ewend, M.G.; Glas, A.M.; Perou, C.M.; Van't Veer, L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res., 2005, 65, 9155-9158.
144. Louahed, J.; Gruselle, O.; Gaulis, S.; Coche, T.; Eggermont, A.M.; Kruit, W.H.; Dreno, B.; Chiarion Sileni, V.; Lehmann, F.; Brichard, V. G. Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J. Clin. Oncol., 2008, 26 Abs, 90.
145. Vansteenkiste, J.; Zielinski, M.; Dahabreh, I.; Linder, A.; Lehmann, F.; Gruselle, O.; Therasse, P.; Louahed, J.; Brichard, V. G. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2008, 26, May 20 suppl, abstr 7501).
146. Oettgen, H. F.; Old, L.J. The history of cancer immunotherapy. 1991, JB Lippincott, 87-119.
147. Klein G.; Sjogren, H.O.; Klein, E.; Hellestrom, K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer. Res.,1960, 20, 1561-1572.
148. Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer. Res., 1943, 3, 323-326.
149. Old, L. J.; Boyse, E.A.; Clarke, D.A.; Carswell, E.A. Antigenic properties of chemically induced tumors. Ann. NY. Acad. Sci., 1962, 101, 80-106.
150. Srivastava, P. K. Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin. Immunol., 1996, 8, 295-302.
151. Hoos, A. andLevey, D.L. Vaccination with heat shock proteinpeptide complexes: from basic science to clinical applications. Expert. Rev. Vaccines., 2003, 2, 369-379.
152. Srivastava, P. K.; Menoret, A.; Basu, S.; Binder, R.J.; McQuade, K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity., 1998, 8, 657-665.
153. Suto, R.; Srivastava, P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science, 1995, 269, 1585-1588.
154. Castelli, C.; Ciupitu, A.M.; Rini, F.; Rivoltini, L.; Mazzocchi, A.; Kiessling, R.; Parmiani, G. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res., 2001, 61, 222-227.
155. Udono, H.; Srivastava, P.K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol., 1994, 152, 5398-5403.
156. Binder, R. J.; Han, D.K.; Srivastava, P.K. CD91: a receptor for heat shock protein gp96. Nat. Immunol., 2000, 1, 151-155.
157. Basu, S.; Binder, R.J.; Ramalingam, T.; Srivastava, P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity., 2001, 14, 303-313.
158. Vabulas, R. M.; Ahmad-Nejad, P.; Ghose, S.; Kirschning, C.J.; Issels, R.D.; Wagner, H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem., 2002, 277, 15107-15112.
159. Asea, A.; Kraeft, S.K.; Kurt-Jones, E.A.; Stevenson, M.A.; Chen, L.B.; Finberg, R.W.; Koo, G.C.; Calderwood, S.K. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med., 2000, 6, 435-442.
160. Berwin, B.; Hart, J.P.; Pizzo, S.V.; Nicchitta, C.V. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J. Immunol., 2002, 168, 4282-4286.
161. Srivastava, P. K. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr. Oncol. Rep., 2005, 7, 104-108.
162. Lehner, T.; Bergmeier, L.A.; Wang, Y.; Tao, L.; Sing, M.; Spallek, R.; van der, Z.R. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur. J. Immunol., 2000, 30, 594-603.
163. Pilla, L.; Patuzzo, R.; Rivoltini, L.; Maio, M.; Pennacchioli, E.; Lamaj, E.; Maurichi, A.; Massarut, S.; Marchiano, A.; Santantonio, C.; Tosi, D.; Arienti, F.; Cova, A.; Sovena, G.; Piris, A.; Nonaka, D.; Bersani, I.; Di Florio, A.; Luigi, M.; Srivastava, P.K.; Hoos, A.; Santinami, M.; Parmiani, G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer. Immunol., Immunother., 2006, 55, 958-968.
164. Elsner, L.; Muppala, V.; Gehrmann, M.; Lozano, J.; Malzahn, D.; Bickeboller, H.; Brunner, E.; Zientkowska, M.; Herrmann, T.; Walter, L.; Alves, F.; Multhoff, G.; Dressel, R. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J. Immunol., 2007, 179, 5523-5533.
165. Singh-Jasuja, H.; Scherer, H.U.; Hilf, N.; Arnold-Schild, D.; Rammensee, H.G.; Toes, R.E.; Schild, H. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol., 2000, 30, 2211-2215.
166. Binder, R. J.; Anderson, K.M.; Basu, S.; Srivastava, P.K. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J. Immunol., 2000, 165, 6029-6035.
167. Tamura, Y.; Peng, P.; Liu, K.; Daou, M.; Srivastava, P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science, 1997, 278, 117-120.
168. Nicchitta, C. V. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr. Opin. Immunol.,1998, 10, 103-109.
169. Huang, X. F.; Ren, W.; Rollins, L.; Pittman, P.; Shah, M.; Shen, L.; Gu, Q.; Strube, R.; Hu, F.; Chen, S.Y. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer. Res., 2003, 63, 7321-7329.
170. Eton, O. Autologous tumor-derived heat-shock-protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Proc. Am. Assoc. Cancer Res., (AACR). 2000, 41,
171. Velazquez, E. F.; Jungbluth, A.A.; Yancovitz, M.; Gnjatic, S.; Adams, S.; O'Neill, D.; Zavilevich, K.; Albukh, T.; Christos, P.; Mazumdar, M.; Pavlick, A.; Polsky, D.; Shapiro, R.; Berman, R.; Spira, J.; Busam, K.; Osman, I.; Bhardwaj, N. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer. Immun., 2007, 7, 11-
172. Riener, M. O.; Wild, P.J.; Soll, C.; Knuth, A.; Jin, B.; Jungbluth, A.; Hellerbrand, C.; Clavien, P.A.; Moch, H.; Jochum, W. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int. J. Cancer., 2009, 124, 352-357.
173. Hundemer, M.; Schmidt, S.; Condomines, M.; Lupu, A.; Hose, D.; Moos, M.; Cremer, F.; Kleist, C.; Terness, P.; Belle, S.; Ho, A.D.; Goldschmidt, H.; Klein, B.; Christensen, O. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp. Hematol., 2006, 34, 486-496.
174. Atanackovic, D.; Luetkens, T.; Hildebrandt, Y.; Arfsten, J.; Bartels, K.; Horn, C.; Stahl, T.; Cao, Y.; Zander, A.R.; Bokemeyer, C.; Kroger, N. Longitudinal analysis and prognostic effect of cancertestis antigen expression in multiple myeloma. Clin. Cancer. Res., 2009, 15, 1343-1352.
175. Dhodapkar, M. V.; Osman, K.; Teruya-Feldstein, J.; Filippa, D.; Hedvat, C.V.; Iversen, K.; Kolb, D.; Geller, M.D.; Hassoun, H.; Kewalramani, T.; Comenzo, R.L.; Coplan, K.; Chen, Y.T.; Jungbluth, A.A. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun., 2003, 3, 9-
176. Yakirevich, E.; Sabo, E.; Lavie, O.; Mazareb, S.; Spagnoli, G.C.; Resnick, M.B. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin. Cancer Res., 2003, 9, 6453-6460.
177. Kim, J.; Reber, H.A.; Hines, O.J.; Kazanjian, K.K.; Tran, A.; Ye, X.; Amersi, F.F.; Martinez, S.R.; Dry, S.M.; Bilchik, A.J.; Hoon, D.S. The clinical significance of MAGEA3 expression in pancreatic cancer. Int. J. Cancer, 2006, 118, 2269-2275.
178. Heike, M. Pilot trial of vaccination with autologous tumour-derived Gp-96 heat shock pProtein-peptide complex (HSPPC-96) in patients after surgery for gastric carcinoma. Proc. Am. Soc. Clin. Onc, 2000, 19,
179. Hertkorn, C.;Lehr, A.;Woelfel, T.; Junginger, T.; Dippold, W.G.; Galle, P. R.; Bernhard, H.; Lewis, J. J.; Srivastava, P. K.; Heike, M. Phase I trial of vaccination with autologous-tumor derived gp96 (oncophage) in patients after surgery for gastric cancer. Proc. Am. Soc. Clin. Onc, 2002, 21, (abstr 117)
180. Li, Z.; Nash, J.D.; Qiao, Y.; Kulko, J. M.; Wilcox, D. K.; Gaffney, J.; Runowicz, C. D.; Simonich, S. A.; Liu, B.; Srivastava, P. K. An autologous tumor-derived heat shock protein vaccine for high risk ovarian cancer. Proc. Am. Soc. Clin. Onc, Annual Meeting Proceedings. 2005, Vol 23, No. 16S, Part I of II (June 1 Suppl)
181. Jonasch, E.; Wood, C.; Tamboli, P.; Pagliaro, L.C.; Tu, S.M.;Kim, J.; Srivastava, P.; Perez, C.; Isakov, L.; Tannir, N. Vaccination of metastatic renal cell carcinoma patients with autologous tumourderived vitespen vaccine: clinical findings. Br. J. Cancer., 2008, 98, 1336-1341.
182. Wood, C. G.; Srivastava, P.; Lacombe, L.; Lacombe, L.; Gorelov, A. I.; Gorelov, S.; Mulders, P.; Zielinski, H.; Teofilovici, F.; Isakov, L.; Escudier, B. Survival update from multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J. Clin. Oncol., 2009, (15 suppl) abs 3009.
183. Wood, C.; Srivastava, P.; Bukowski, R.; Lacombe, L.; Gorelov, A.I.; Gorelov, S.; Mulders, P.; Zielinski, H.; Hoos, A.; Teofilovici, F.; Isakov, L.; Flanigan, R.; Figlin, R.; Gupta, R.; Escudier, B. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet, 2008, 372, 145-154.
184. Mazzaferro, V.; Coppa, J.; Carrabba, M.G.; Rivoltini, L.; Schiavo, M.; Regalia, E.; Mariani, L.; Camerini, T.; Marchiano, A.; Andreola, S.; Camerini, R.; Corsi, M.; Lewis, J.J.; Srivastava, P.K.; Parmiani, G. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer. Res., 2003, 9, 3235-3245.
185. Dong, J.; Wei, J. Effective vaccines of autologous cancer-derived heat shock protein gp70-complexes in patients with cancer malignancies (pancreatic carcinoma, colo-rectal cancer). Proc. Am. Soc. Clin. Onc, ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Suppl),
186. Maki, E.; Livingston, P.O.; Lewis, J.J.; Janetzki, S.; Klimstra, D.; Desantis, D.; Srivastava, P.K.; Brennan, M.F. A Phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Digest. Dis. Sci., 2007, 52, 1964-1972.
187. Parsa, A.; Crane, C.; Wilson, S.; Autologous tumor derived gp96 evokes a tumor specific immune response in recurrent glioma patients that correlates with clinical response to therapy. AACR-NCIEORTC. 2007,
188. Parsa, A.; Aghi, M.; Ahn, B.; Bruce, J. Autologous heat shock protein vaccine for patients with newly diagnosed and recurrent glioblastoma. International Conference on Brain Tumor Research and Therapy. 2010,
189. Younes, A.; Fayad, L.E.; Pro, B. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low grade lymphoma. Proc. Am. Soc. Clin. Onc, (ASCO). 2003, 22,
190. Younes, A. A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma. Clin. Lymphoma., 2003, 4, 183-185.
191. Oki, Y.; McLaughlin, P.; Fayad, L.E.; Pro, B.; Mansfield, P.F.; Clayman, G.L.; Medeiros, L.J.; Kwak, L.W.; Srivastava, P.K.; Younes, A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer., 2007, 109, 77-83.
192. Li, Z. Autologous leucocyte-derived heat shock protein 70-peptide complex as a vaccine for chronic myelogenous leukemia in chronic phase: an updated phase I. Blood, 2003, 102,